In late March 2013, DARA Bio (DARA) filed its Form 10K annual report highlighting both the business and financial updates from 2012. Below we discuss the key drivers at DARA, and why we believe the company is a vastly undervalued emerging specialty pharmaceutical story.
Vascular Nanotransfer Technologies (VNT) says it has developed the industry’s most versatile Drug-Coated-Balloon (DCB) platform designed to deliver a wide variety of drugs for best-in-class DCB applications.
The San Diego-based pharmaceutical company has five approved products internationally, covering erectile dysfunction (Vitaros), side effects of cancer therapy (Totect and Granisol), coronary artery disease (Nitromist) and dry mouth (Aquoral). After a series of successes in strategic partnerships, acquisitions, peer review and clinical data in Q3, the company is garnering some serious attention.
At OneMedPlace, our goal is to be your eyes and ears to the biotech and life sciences sector: putting into perspective what we’ve seen so far, and providing you with snapshots of and what’s upcoming.
Apricus Bio VP Edward Cox discusses the future of drug delivery technology in the rapidly expanding world of personalized medicine.
IntelGenx is at the forefront of the industry with CPI-300 being the only single dose 450 mg formulation of Bupropion HCl approved by the FDA.
Bio-Path Holdings has developed a powerful drug delivery technology that utilizes cell-like drug carriers, termed liposomes, which avoid drug breakdown.
In 2006, 2-year-old Emily Jerry was killed when a technician mixed her chemotherapy drug with a saline solution 26 times above normal.
The introduction of delivering a drug on film might be the best thing since sliced bread. Similar to breath enhancement strips, this edible film technology is in studies to be used for erectile dysfunction, migraine, insomnia, bipolar disorder, and pain management!
ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX), with its leading innovations in anti-cancer drug development has just announced that they have been successful in sending their ANX-530 (Exelbine) New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) date of September 1, 2011.
Copyright © 2024 | WordPress Theme by MH Themes